The ability of eribulin to synergize with STING agonists in vitro (Figure 3) and enhance the in vivo immunological response to either tumors or pharmacological STING agonists (Figure 7) prompted an evaluation of the antitumor efficacy of eribulin with ADU-S100 in an aggressive genetically induced mammary tumor model. This evidence concerns the gene STING1 and breast cancer.